ELAN Q1 2023 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.3B+2.5% YoY

Gross Profit

$629M50.0% margin

Operating Income

$221M17.6% margin

Net Income

$103M8.2% margin

EPS (Diluted)

$0.21

QoQ Revenue Growth

+27.2%

Cash Flow

Operating Cash Flow

-$145M

Free Cash Flow

-$183M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$15.8B

Total Liabilities

$8.3B

Stockholders' Equity

$7.5B

Cash & Equivalents

$318M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$1.2B	+2.5%
Gross Profit	$629M	$580M	+8.4%
Operating Income	$221M	$176M	+25.6%
Net Income	$103M	$51M	+102.0%

Revenue Segments

Pet Health

$675M38%

Farm Animal

$573M32%

Cattle

$248M14%

Poultry

$183M10%

Swine

$102M6%

Contract Manufacturing

$9M1%

Geographic Segments

Non-US

$714M57%

UNITED STATES

$543M43%